IFPMA - International Federation of Pharmaceutical Manufacturers & Associations
Find out more on X.Find out more on LinkedIn.Find out more on Facebook.Find out more on Youtube.
Return to all milestones

Five priorities for future pandemic preparedness and response

As the global architecture for pandemic preparedness and response is discussed, the innovative pharmaceutical industry shares practical solutions and recommends focusing on five priorities. These include ensuring the thriving innovation ecosystem continues and guarantees access to pathogens, taking steps now to agree impactful and practical equitable access measures, sustaining manufacturing capacity in more geographical regions, supporting open borders and the removal of trade restrictions, and contributing to ongoing efforts to build greater country readiness to anticipate and respond to future pandemics. In addition, collaboration and sustainable financing mechanisms so countries can prepare and respond to pandemics remain critical to the success for future pandemic response.

Spanish, Italian, and French health authorities expand recommendations for use of Novavax COVID-19 vaccine.

The WHO updates its recommendations for the use of COVID-19 therapeutics, considering new evidence of the reduction of effectiveness against circulating Omicron variants.

Shionogi announces the initiation of a Phase1/2/3 clinical trial in Japanese pediatric subjects for the COVID-19 recombinant protein-based vaccine, S-268019.

An independent report commissioned by IFPMA points to an increased politicization of access to samples and sequence information on pathogens, finding serious shortcomings, including the fact that the international framework on accessing and sharing pathogens is putting severe strain on the global health community's ability to control future outbreaks.

Roche launches a COVID-19 PCR test to detect the fast spreading XBB.1.5 Omicron sub-variant, after announcing that the sensitivity of its SARS-CoV-2 Rapid Antigen Tests' against Omicron variant has been confirmed via additional studies.

The European Medicines Agency (EMA) recommends to convert Pfizer's COVID-19 antiviral, Paxlovid, from conditional market authorization to full market authorization.

The International Pandemic Preparedness Secretariat (IPPS) publishes the Second Implementation Report of the 100 Days Mission, identifying six focus areas for international effort and support in 2023. The report underlines the importance of access to pathogens and underscores the value of the Berlin Declaration proposal to ensure equitable access to countermeasures.

Shionogi advances Ensitrelvir Fumaric Acid COVID-19 antiviral clinical program.

Gilead Sciences announces that three different real world studies confirm the ability of its COVID-19 antiviral, remdesivir, to reduce risk of mortality in hospitalized patients.

Pfizer and BioNTech submit supplemental biologics license application for US FDA approval of Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for ages 12 years and older as primary series or booster.

Previous
milestone
Next
milestone